Diagnosis and management of smoldering multiple myeloma: the razor’s edge between clonality and cancer

Eli Muchtar, Shaji K Kumar, Hila Magen, Morie Gertz

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Smoldering multiple myeloma (SMM) is a rare plasma cell disorder, and as the disease is asymptomatic, diagnosis is often incidental. SMM is characterized by increased marrow infiltration by clonal plasma cells and/or elevated serum M-protein in the absence of a myeloma-defining event (MDE). In recent years, SMM has gained increased attention owing to a broadening of the criteria for MDE, which include apart from the CRAB criteria, three additional parameters. Survival advantage may be offered by early treatment in the high-risk subset, based on a single trial. In this review, we assess the risk factors and models for progression to multiple myeloma. A review of our diagnostic and management approaches to SMM is presented.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - Jun 7 2017

Fingerprint

Multiple Myeloma
Neoplasms
Plasma Cells
Asymptomatic Diseases
Blood Proteins
Bone Marrow

Keywords

  • early intervention
  • models
  • progression
  • Risk
  • survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Diagnosis and management of smoldering multiple myeloma : the razor’s edge between clonality and cancer. / Muchtar, Eli; Kumar, Shaji K; Magen, Hila; Gertz, Morie.

In: Leukemia and Lymphoma, 07.06.2017, p. 1-12.

Research output: Contribution to journalArticle

@article{9665b201691a487cb8b59512981e6649,
title = "Diagnosis and management of smoldering multiple myeloma: the razor’s edge between clonality and cancer",
abstract = "Smoldering multiple myeloma (SMM) is a rare plasma cell disorder, and as the disease is asymptomatic, diagnosis is often incidental. SMM is characterized by increased marrow infiltration by clonal plasma cells and/or elevated serum M-protein in the absence of a myeloma-defining event (MDE). In recent years, SMM has gained increased attention owing to a broadening of the criteria for MDE, which include apart from the CRAB criteria, three additional parameters. Survival advantage may be offered by early treatment in the high-risk subset, based on a single trial. In this review, we assess the risk factors and models for progression to multiple myeloma. A review of our diagnostic and management approaches to SMM is presented.",
keywords = "early intervention, models, progression, Risk, survival",
author = "Eli Muchtar and Kumar, {Shaji K} and Hila Magen and Morie Gertz",
year = "2017",
month = "6",
day = "7",
doi = "10.1080/10428194.2017.1334124",
language = "English (US)",
pages = "1--12",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Diagnosis and management of smoldering multiple myeloma

T2 - the razor’s edge between clonality and cancer

AU - Muchtar, Eli

AU - Kumar, Shaji K

AU - Magen, Hila

AU - Gertz, Morie

PY - 2017/6/7

Y1 - 2017/6/7

N2 - Smoldering multiple myeloma (SMM) is a rare plasma cell disorder, and as the disease is asymptomatic, diagnosis is often incidental. SMM is characterized by increased marrow infiltration by clonal plasma cells and/or elevated serum M-protein in the absence of a myeloma-defining event (MDE). In recent years, SMM has gained increased attention owing to a broadening of the criteria for MDE, which include apart from the CRAB criteria, three additional parameters. Survival advantage may be offered by early treatment in the high-risk subset, based on a single trial. In this review, we assess the risk factors and models for progression to multiple myeloma. A review of our diagnostic and management approaches to SMM is presented.

AB - Smoldering multiple myeloma (SMM) is a rare plasma cell disorder, and as the disease is asymptomatic, diagnosis is often incidental. SMM is characterized by increased marrow infiltration by clonal plasma cells and/or elevated serum M-protein in the absence of a myeloma-defining event (MDE). In recent years, SMM has gained increased attention owing to a broadening of the criteria for MDE, which include apart from the CRAB criteria, three additional parameters. Survival advantage may be offered by early treatment in the high-risk subset, based on a single trial. In this review, we assess the risk factors and models for progression to multiple myeloma. A review of our diagnostic and management approaches to SMM is presented.

KW - early intervention

KW - models

KW - progression

KW - Risk

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85020377940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020377940&partnerID=8YFLogxK

U2 - 10.1080/10428194.2017.1334124

DO - 10.1080/10428194.2017.1334124

M3 - Article

C2 - 28592156

AN - SCOPUS:85020377940

SP - 1

EP - 12

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -